FindTrial
Sign In

VRC-PBSPLA043-00-VP

OTHER2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chikungunya Virus InfectionFlaviviral DiseasesFlaviviridae InfectionsFlavivirus InfectionsRNA Virus InfectionsVirus DiseasesZika VirusZika Virus Infection

Phase 2

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
CompletedNCT02562482
National Institute of Allergy and Infectious Diseases (NIAID)Chikungunya Virus Infection
Start: 2015-11-18End: 2018-03-06Updated: 2020-10-22
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
CompletedNCT03110770
National Institute of Allergy and Infectious Diseases (NIAID)Flaviviral Diseases, Flaviviridae Infections, Flavivirus Infections +4
Start: 2017-03-29End: 2019-10-04Updated: 2024-01-31

Related Papers

Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals
Vaccine2023-09-095 citations
Differential dengue antibody responses in recipients of a Zika DNA vaccine are governed by dengue immune history
The Journal of Immunology2023-05-01
Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes
JAMA2020-04-14101 citations
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
2017-12-05230 citations